Cited by 53Advanced Glycation End Products researchDialysis and Renal Disease ManagementChronic Kidney Disease and Diabetes

Glycation free adduct accumulation in renal disease: the new AGE

Thornalley, Paul J.·2005·Pediatric Nephrology

Abstract

Glycation adducts formed in the later stages of protein glycation reactions, advanced glycation endproducts (AGEs), are a class of uraemic toxin. Protein glycation was viewed originally as a post-translational modification that accumulated mostly on extracellular proteins. We now know that AGE residues are also formed on short-lived cellular and extracellular proteins. Cellular proteolysis forms AGE free adducts from these proteins, which are released into plasma for urinary excretion. AGE free adducts are also absorbed from food. AGE free adducts are the major molecular form by which AGEs are excreted in urine. They normally have high renal clearance, but this declines markedly in chronic renal failure patients, leading to profound increases in plasma AGE free adducts. Accumulation of plasma AGE free adducts is increased further in end stage renal disease patients on peritoneal dialysis and haemodialysis by increased AGE formation. The impact of AGEs absorbed from food is probably most marked for undialysed patients with mild uraemia. The toxicity of AGEs has been associated with resistance of the extracellular matrix to proteolysis and AGE receptor-mediated responses. AGE free adducts may also contribute to vascular disease in uraemia. They represent an important new age for glycation research in nephrology.

Integrity signals

Registry

Crossref · 10.1007/s00467-005-2011-9

Cites

66 of 66 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Adipokine secretion profiles differ between subcutaneous and abdominal adipose tissues.

    “In addition, the profile of adipokines produced is dissimilar between the subcutaneous and abdominal adipose tissues.”
  • Leptin is preferentially expressed and secreted by subcutaneous adipose tissue, while adiponectin, visfatin, omentin, resistin, PAI-1, IL-8, IL-7, IL-1a, MCP-1, TGF-b, growth-related oncogene, CCL5 and MIP-1b are expressed more in abdominal fat.

    “Thus, leptin is preferentially expressed and secreted by subcutaneous adipose tissue (52) , while the expression of adiponectin, visfatin, omentin, resistin, PAI-1, IL-8, IL-7, IL-1a, MCP-1, TGF-b, growth-related oncogena, CCL5 and MIP-1b is higher in abdominal fat.”
  • IL-6 and TNF-a appear to be synthesised equally by different adipose tissue sites.

    “In contrast to such distributions, there are reports that IL-6 and TNF-a seem to be equally synthesised by the different sites (28,36,53 -59) .”
  • Adipose tissue macrophages may contribute to maintenance of the low-grade inflammatory state linked to obesity.

    “Adipose tissue macrophages may contribute to the maintenance of the low-grade inflammatory state linked to obesity (36) .”
  • Reduced secretion of pro-inflammatory mediators from adipocytes or adipose tissue macrophages likely contributes to the effect of weight loss.

    “On the other hand, it seems likely that reduced secretion of pro-inflammatory mediators from adipocytes or activated macrophages of adipose tissue contributes to the effect of weight loss (31,36,65,67,142) .”

Cites

Flagged first, then by citations

1 of the 67 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Thornalley, P. J.
Affiliations
University of Essex (GB)
Corresponding author
Thornalley, Paul J.
Venue
Pediatric Nephrology
Published
2005-08-24
Volume
20
Issue
11
Pages
1515-1522
ISSN
  • 0931-041X (ISSN-L)
  • 1432-198X
OpenAlex
W2135210722
Cited by
53
References
67
Citations by year
2026: 2 · 2023: 1 · 2022: 4 · 2021: 1 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 6 · 2015: 5 · 2014: 3 · 2013: 2 · 2012: 1
FWCI
0.50
Type
journal article
Language
en
Open access
closed
Locations
  • Pediatric Nephrology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Wellcome Trust
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
  • Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
  • Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
Keywords
advanced glycation end products, protein glycation, uremic toxins, chronic kidney disease, end-stage renal disease, dialysis, renal clearance, AGE receptor, extracellular matrix
MeSH terms
Amino Acid Oxidoreductases, Food Analysis, Humans, Imidazoles, Kidney, Kidney Diseases, Glycation End Products, Advanced

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review